Transcutaneous pO₂ Monitoring in PICU
ConditionPediatric Critical Illness
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-18
SponsorIstanbul Medeniyet University
About this trial
Arterial blood gas analysis is commonly used in pediatric intensive care units (PICUs) to assess oxygen and carbon dioxide levels in critically ill children. However, arterial blood sampling is invasive, can be painful, and may need to be repeated frequently. Transcutaneous monitoring provides a noninvasive method to continuously measure oxygen (pO₂) and carbon dioxide (pCO₂) levels through the skin, but its accuracy in critically ill pediatric patients requires further evaluation.
The purpose of this observational study is to compare transcutaneous pO₂ and pCO₂ measurements with arterial blood gas values in pediatric intensive care unit patients. By analyzing paired measurements obtained simultaneously during routine clinical care, this study aims to evaluate the agreement between transcutaneous and arterial measurements, with a particular focus on whether transcutaneous pO₂ can serve as a reliable alternative to arterial sampling.
The results of this study may help clarify the role of transcutaneous monitoring in pediatric intensive care and may contribute to reducing the need for invasive blood sampling in selected patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age between 1 month and 18 years
Admission to the Pediatric Intensive Care Unit (PICU)
Presence of an arterial catheter allowing arterial blood gas (ABG) sampling
Simultaneous or paired transcutaneous pCO₂ and pO₂ monitoring available
Disqualifiers
Severe skin disease, burns, or local skin infection at the transcutaneous sensor site
Severe peripheral perfusion impairment (e.g., refractory shock or high-dose vasopressor support)
Congenital or acquired conditions interfering with accurate transcutaneous measurements
Technical failure or inability to obtain reliable transcutaneous readings
Trial population
This study will include pediatric patients aged 1 month to 18 years admitted to the Pediatric Intensive Care Unit (PICU) who undergo arterial blood gas analysis and concurrent transcutaneous pCO₂ and pO₂ monitoring as part of routine clinical care. Patients with an indwelling arterial catheter and adequate peripheral perfusion allowing reliable transcutaneous measurements will be eligible. The study population represents critically ill children requiring close respiratory and hemodynamic monitoring in the PICU setting.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Agreement Between Transcutaneous pO₂ and Arterial pO₂
Agreement between transcutaneous oxygen partial pressure (Tc pO₂) and arterial oxygen partial pressure (PaO₂) obtained from arterial blood gas analysis in pediatric intensive care unit patients.
Time frame
At the time of each paired transcutaneous monitoring and arterial blood gas measurement during PICU admission (up to 28 days)Secondary outcomes
1
Agreement Between Transcutaneous pCO₂ and Arterial pCO₂
Agreement between transcutaneous carbon dioxide partial pressure (Tc pCO₂) and arterial carbon dioxide partial pressure (PaCO₂) obtained from arterial blood gas analysis in pediatric intensive care unit patients.
Time frame
At the time of each paired transcutaneous monitoring and arterial blood gas measurement during PICU admission (up to 28 days)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov